Plant ID: NPO29653
Plant Latin Name: Hippophae fructus
Taxonomy Genus: Hippophae
Taxonomy Family: Elaeagnaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
ADRA2B; HTR1E; ADORA3; HTR7; FFAR1; HTR1F; HTR2A; FFAR4; HTR5A; HTR1B; DRD2; HTR4; HTR1D; HTR2B; HTR1A; HTR2C; HTR6; DRD3; | |
TSHR; NPSR1; | |
TDP1; RECQL; GLO1; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; TNKS; TNKS2; APEX1; POLB; | |
ACHE; | |
CDC25B; | |
HTR3A; | |
TOP2A; | |
PIM1; MET; AXL; FLT3; CDK1; KDR; IGF1R; AURKB; | |
CA2; CA12; CA14; CA7; CA4; | |
PPARA; | |
AR; PGR; NR3C2; NR3C1; | |
NR1H4; | |
RORC; | |
TYR; | |
MMP1; MMP2; MMP9; | |
AHR; TP53; NFKB1; | |
SLCO1B1; | |
LMNA; FABP3; FABP5; SERPINA6; FABP4; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | HTR1E | Serotonin 1e (5-HT1e) receptor | P28566 | CHEMBL2182 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | HTR1F | Serotonin 1f (5-HT1f) receptor | P30939 | CHEMBL1805 |
Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Small molecule receptor (family A GPCR) | HTR4 | Serotonin 4 (5-HT4) receptor | Q13639 | CHEMBL1875 |
Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 6.748E-12 | 5.248E-09 | ADORA3, ADRA2B, AXL, DRD2, DRD3, FFAR1, FFAR4, FLT3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, SLCO1B1, TSHR |
BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 2.096E-10 | 1.170E-07 | HTR1A, HTR1B, HTR5A, HTR7 |
BP | Unclassified; | GO:0042310; vasoconstriction | 1.237E-09 | 5.536E-07 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.423E-09 | 6.077E-07 | AR, CA12, CA2, CA4, CA7, GLO1, L3MBTL1, MMP1, MMP2, MMP9, NR1H4, NR3C1, NR3C2, PGR, PPARA, RORC, TNKS, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.245E-09 | 8.577E-07 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.900E-09 | 1.089E-06 | AR, NR1H4, NR3C1, NR3C2, PGR, PPARA, RORC |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.424E-08 | 8.669E-06 | AHR, AR, NR1H4, PGR, PPARA, RORC |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.714E-08 | 9.295E-06 | ALOX12, AR, CDC25B, CDK1, DRD2, DRD3, FLT3, HTR1A, HTR1B, HTR2A, HTR2B, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.203E-08 | 1.017E-05 | AR, NR1H4, NR3C1, NR3C2, PGR, RORC, SERPINA6 |
BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 6.776E-08 | 1.604E-05 | DRD2, DRD3, HTR1B, HTR2B |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.112E-07 | 2.497E-05 | CA2, CA7, DRD2, DRD3, HTR2A, HTR2B, HTR2C, KDR, NPSR1 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.436E-07 | 3.134E-05 | ALOX12, AR, AURKB, AXL, CDK1, FFAR4, GLO1, HTR2B, IGF1R, KDR, LMNA, MMP9, NFKB1, NR1H4, PIM1, TP53 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.959E-07 | 3.951E-05 | AR, CDK1, NR1H4, NR3C1, NR3C2, PGR, PPARA, RORC |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.891E-07 | 7.367E-05 | AHR, AR, NR1H4, NR3C1, PGR, PIM1, PPARA, RORC |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.622E-07 | 8.602E-05 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1, DRD2, PPARA, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 5.237E-07 | 9.503E-05 | ADRA2B, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7 |
BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 5.591E-07 | 1.006E-04 | HTR2A, HTR2B, HTR2C |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.215E-07 | 1.237E-04 | AR, NR1H4, NR3C1, NR3C2, PGR, PPARA, RORC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.438E-07 | 1.265E-04 | CA12, CA14, CA2, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 9.548E-07 | 1.587E-04 | ALOX15, DRD2, FFAR4, HTR2A, HTR2B, HTR2C, KDR, NOX4 |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 2.218E-06 | 3.241E-04 | DRD2, DRD3, PPARA, RORC, TOP2A, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 2.305E-06 | 3.302E-04 | AHR, DRD2, DRD3, PPARA, RORC |
BP | GO:0032502; developmental process | GO:0007568; aging | 3.138E-06 | 4.381E-04 | APEX1, AURKB, CDK1, CYP1A1, HTR2A, NOX4, POLB, TP53 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 3.438E-06 | 4.759E-04 | FABP3, FABP4, FABP5, FFAR4 |
BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 3.999E-06 | 5.342E-04 | DRD2, DRD3, HTR1B, HTR2A |
BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 5.917E-06 | 7.377E-04 | CDK1, DRD3, HTR1B, HTR3A, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.616E-06 | 8.094E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 6.942E-06 | 8.397E-04 | CA2, CA7, DRD2, HTR1B |
MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.404E-27 | 1.529E-23 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR7 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 8.524E-06 | 1.003E-03 | APEX1, AR, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, NR3C1, RORC |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.124E-05 | 1.281E-03 | CA12, CA2, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 1.488E-05 | 1.565E-03 | HTR2A, HTR2C |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.488E-05 | 1.565E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.488E-05 | 1.565E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.488E-05 | 1.565E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 1.488E-05 | 1.565E-03 | HTR2A, HTR2C |
BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 1.985E-05 | 2.048E-03 | DRD2, HTR1B, HTR2A |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.178E-05 | 2.217E-03 | APEX1, HTR1B, IGF1R, MMP2, NFKB1, NOX4, NR1H4, TP53, TSHR |
BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 2.768E-05 | 2.667E-03 | DRD2, HTR2A, HTR2B, HTR2C |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.768E-05 | 2.667E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 3.676E-05 | 3.451E-03 | AURKB, TNKS, TNKS2 |
BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 4.037E-05 | 3.741E-03 | ADORA3, ALOX12, APEX1, CYP1B1, DRD2, IGF1R, KDR, LMNA, MET, MMP9, NOX4, TP53 |
BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 4.452E-05 | 3.909E-03 | AR, PGR |
BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 4.452E-05 | 3.909E-03 | DRD2, DRD3 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.452E-05 | 3.909E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.452E-05 | 3.909E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.452E-05 | 3.909E-03 | ALOX12, ALOX15 |
BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 6.112E-05 | 5.080E-03 | DRD2, DRD3, HTR2A |
BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 6.167E-05 | 5.106E-03 | APEX1, FABP3, FFAR4, IGF1R, NFKB1, PPARA, TP53, TSHR |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 6.559E-05 | 5.410E-03 | CYP1A1, DRD2, LMNA, MMP2, NOX4, PPARA, TP53 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.111E-05 | 5.735E-03 | CYP1A1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.111E-05 | 5.735E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0023052; signaling | GO:0046883; regulation of hormone secretion | 7.222E-05 | 5.803E-03 | ADRA2B, DRD2, FFAR1, HTR1A, HTR2A, HTR2C, NR1H4 |
BP | GO:0009987; cellular process | GO:1903531; negative regulation of secretion by cell | 8.040E-05 | 6.366E-03 | ADRA2B, DRD2, DRD3, FFAR4, HTR1B, NR1H4 |
BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 8.116E-05 | 6.386E-03 | AURKB, CDK1, TNKS, TNKS2 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 8.211E-05 | 6.408E-03 | HTR1B, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.881E-05 | 6.809E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.881E-05 | 6.809E-03 | CYP1A1, CYP1A2 |
BP | GO:0032501; multicellular organismal process | GO:0014827; intestine smooth muscle contraction | 8.881E-05 | 6.809E-03 | HTR1D, HTR2B |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 9.252E-05 | 6.995E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.416E-05 | 7.045E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.416E-05 | 7.045E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.216E-04 | 8.739E-03 | FABP3, FABP4, FABP5 |
BP | GO:0050896; response to stimulus | GO:0046688; response to copper ion | 1.216E-04 | 8.739E-03 | CDK1, CYP1A1, CYP1A2 |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.297E-04 | 9.229E-03 | ALOX15, AURKB, DRD3, KDR, MET, MMP9, NOX4, TNKS, TNKS2, TP53 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.335E-04 | 9.470E-03 | DRD2, DRD3, FABP3, PPARA |
BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.214E-23 | 4.405E-20 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.214E-23 | 4.405E-20 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
MF | Unclassified; | GO:0004872; receptor activity | 4.301E-18 | 6.689E-15 | ADORA3, ADRA2B, AHR, AR, AXL, DRD2, DRD3, FFAR1, FFAR4, FLT3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, NR1H4, NR3C1, NR3C2, PGR, PPARA, RORC, TSHR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.092E-19 | 1.507E-17 | HTR1E, HTR1F, HTR1D, ALOX15, HTR1A, HTR2B, HTR1B, HTR2C, ALOX12, HTR3A, HTR2A, HTR5A, HTR4, HTR6, HTR7 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 9.525E-18 | 6.573E-16 | HTR1E, HTR1F, HTR1D, HTR1A, HTR2B, HTR1B, HTR2C, HTR2A, HTR5A, HTR4, NR3C1, ADRA2B, TSHR, HTR6, HTR7, ADORA3, DRD2, DRD3 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.016E-10 | 9.275E-09 | HTR6, HTR1E, HTR1F, HTR1D, HTR1A, HTR1B, HTR4, PPARA, DRD2, NFKB1, TSHR |
09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 6.813E-07 | 1.880E-05 | HTR1E, HTR1F, HTR1D, HTR1A, HTR1B, HTR3A |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.869E-09 | 1.335E-07 | CA12, CA2, CA4, CA7, CA14 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 5.044E-06 | 1.160E-04 | HTR6, HTR7, HTR2B, HTR2C, HTR2A, HTR5A, HTR4 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.727E-05 | 2.648E-04 | AR, FLT3, MMP1, MMP2, MET, TP53, MMP9, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 6.038E-06 | 1.190E-04 | FABP3, FABP4, FABP5, MMP1, PPARA |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.663E-05 | 2.648E-04 | MMP1, MMP2, MMP9, TP53 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.991E-05 | 2.748E-04 | CDK1, HTR2B, HTR2C, HTR2A, DRD2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.686E-05 | 4.624E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.142E-04 | 1.126E-03 | MMP2, KDR, TP53, MMP9, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.885E-05 | 6.767E-04 | FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.242E-04 | 1.143E-03 | PIM1, CYP1B1, TP53, MMP9, MET, NFKB1, CDC25B |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.638E-05 | 7.046E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.499E-04 | 3.018E-03 | AR, TP53, NFKB1, IGF1R |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 5.047E-04 | 3.666E-03 | HTR2B, HTR2C, ALOX12, HTR2A |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 5.047E-04 | 3.666E-03 | CDK1, PGR, CDC25B, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.182E-03 | 8.157E-03 | AR, CDK1, PGR, IGF1R |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.529E-04 | 3.666E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.281E-03 | 8.421E-03 | FLT3, PIM1, NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; HTR1A; |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
NA: NA | Itching | NA | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; DRD2; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR; |
NA: NA | HIV infections | NA | AHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; AR; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
NA: NA | False perceptions | NA | DRD2; |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
NA: NA | Peripheral vasoconstriction | NA | DRD2; |
NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; HTR3A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; HTR1A; HTR1B; HTR1D; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD2; HTR1A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
NA: NA | Episode | NA | HTR1A; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
NA: NA | Corneal vascularity | NA | DRD2; |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
NA: NA | Anxiety disorders | NA | HTR1A; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; NR3C1; HTR2A; HTR2C; HTR6; HTR1A; HTR1B; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; NR3C2; |
NA: NA | Hyperaemia | NA | DRD2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; TP53; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
NA: NA | Schizoaffective disorder | NA | HTR1A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; DRD2; HTR2A; HTR2C; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; HTR1A; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; HTR6; HTR1A; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PGR; |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; DRD3; HTR6; HTR3A; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
NA: NA | Edema | NA | CA2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; AR; FLT3; DRD2; |
NA: NA | Addiction | NA | HTR2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2; |
C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DRD2; |
NA: NA | Non-infectious rhinitis | NA | NR3C1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR6; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; NR3C2; |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; MMP1; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; HTR6; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; HTR2C; HTR6; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C; |
G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; HTR3A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; HTR2A; HTR2B; HTR2C; HTR1A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; FFAR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; MMP2; |
I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Uterine fibroids | D25 | PGR; |
NA: NA | Inflammatory diseases | NA | DRD2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; NR3C1; SERPINA6; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; NR3C1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; HTR6; HTR1A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B; |
E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD2; HTR1A; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; AR; ACHE; DRD2; HTR2C; HTR1A; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
NA: NA | Obstructive airway diseases | NA | SERPINA6; |
NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; HTR3A; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; NR3C1; |
H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; FLT3; |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR; |
NA: NA | Primary insomnia | NA | HTR2C; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
NA: NA | Vomiting | NA | DRD2; HTR3A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | NR3C2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD2; DRD3; HTR2C; HTR1A; HTR1B; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A; |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2; |
I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; HTR1A; HTR1D; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; DRD2; HTR2C; HTR1A; HTR1B; HTR1D; |
I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
NA: NA | Male hypogonadism | NA | AR; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; AR; HTR2A; NR3C2; |
I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; MMP9; TP53; MMP2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
NA: NA | Social phobia | NA | HTR1A; |
NA: NA | Cervical dystonia | NA | HTR1A; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
NA: NA | Malignant essential hypertension | NA | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; AR; NFKB1; FLT3; ACHE; ADORA3; NR3C1; MMP9; TP53; NR3C2; PGR; MMP2; CDC25B; |
J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
NA: NA | Bulimia nervosa | NA | HTR1A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
NA: NA | Schizoaffective disorders | NA | DRD2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; MMP1; TYR; |
NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; NR3C1; SERPINA6; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; AR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD2; DRD3; HTR2A; HTR2C; HTR6; HTR1A; |
I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; NR3C2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; HTR2C; HTR1B; HTR1D; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR2B; HTR1F; HTR1A; HTR1D; |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA3; DRD2; HTR2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; NR3C1; NR3C2; FFAR1; |